Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
Antonio López-Beltrán(University of Córdoba), Rodolfo Montironi(Marche Polytechnic University), Alessia Cimadamore(University of Udine), Nuno Vau(Champalimaud Foundation), Marina Scarpelli(Marche Polytechnic University), Liang Cheng(Brown University), Francesco Massari(Altera (United States)), Ana Blanca(Instituto Maimónides de Investigación Biomédica de Córdoba)
Cited by 289
Related Papers
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
|Modern Pathology|2017|404
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
|Cells|2020|256
The World Health Organization 2016 classification of testicular non‐germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel
|Histopathology|2016|236
Frequent <i>FGFR3</i> mutations in urothelial papilloma
|The Journal of Pathology|2002|189